Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up

Proteasome inhibition is a standard of care for the primary treatment of patients with Waldenström macroglobulinemia (WM). We present the long-term follow-up of a prospective, phase II clinical trial that evaluated the combination of ixazomib, dexamethasone, and rituximab (IDR) in 26 treatment-naive...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Castillo, Jorge J., Meid, Kirsten, Flynn, Catherine A., Chen, Jiaji, Demos, Maria G., Guerrera, Maria L., Kofides, Amanda, Liu, Xia, Munshi, Manit, Tsakmaklis, Nicholas, Patterson, Christopher J., Yang, Guang, Hunter, Zachary, Treon, Steven P.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2020
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7448596/
https://ncbi.nlm.nih.gov/pubmed/32822482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001963
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires